Evidence map›Paper›PMID 41319157›Full record

ArticleJournal of internal medicine2026

Long-term risk of cardiovascular events after COVID-19 in the Swedish adult population-A matched cohort study.

Martin Lindgren, Helen Sjöland, Demir Djekic, Josefina Robertson, Maria Åberg, Erik Thunström, Zacharias Mandalenakis, Jon Edqvist, Christina E Lundberg, Martin Adiels and 1 more

Abstract read
In one paragraph

Article in Journal of internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Martin LindgrenDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID https://orcid.org/0000-0001-8567-0422
Helen SjölandDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID https://orcid.org/0000-0003-1013-542X
Demir DjekicDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Josefina RobertsonDepartment of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Maria ÅbergSchool of Public Health and Community Medicine/Primary Health Care, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Erik ThunströmDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Zacharias MandalenakisDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Jon EdqvistDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Christina E LundbergDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Martin AdielsSchool of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
Annika RosengrenDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Funding

Swedish Heart and Lung Foundation 2021-0345Swedish Research Council 2018-02527Swedish Research Council 2020-05792Swedish Research Council 2021-06525Swedish Research Council VRREG 2019-00193Swedish Research Council for Health, Working Life and Welfare 2021-00304Swedish state under an agreement concerning research and education of doctors ALFGBG-966211Swedish state under an agreement concerning research and education of doctors ALFGBG-971608
6 · The paper itself

Abstract

backgroundThe long-term risk across severity strata of people infected with SARS-CoV-2 has not yet been comprehensively described.

methodsUsing nationwide registries, all COVID-19 cases in Sweden with <2 vaccine doses, with and without initial hospitalization (February 1, 2020 to June 30, 2022), were identified and matched with non-COVID comparators. Participants were followed during the early, intermediate, long-term, and extended phases (365+ days) regarding death, acute myocardial infarction (AMI), ischemic stroke (IS), or heart failure (HF), and a composite of major adverse cardiovascular events (MACEs). Hazard ratios (HRs) were estimated using Cox proportional hazard regression adjusted for age, sex, obesity, hypertension, need of assisted living, Nordic origin, education, and Charlson Comorbidity Index.

resultsWe identified 1,024,623 nonhospitalized (mean age: 40.4 years, 48.1% men) and 49,855 hospitalized (mean age: 58.8 years, 58.9% men) COVID-19 cases who were matched with 1,022,266 and 249,142 non-COVID comparators, respectively. Overall, nonhospitalized cases had no remaining risk of MACE past the early phase following COVID-19 infection. Among hospitalized cases, the risk of MACE remained elevated into the long-term and extended follow-up period (HRs 1.70 [confidence interval (CI) = 1.56-1.86] and 1.62 [CI = 1.51-1.72]) compared with comparators. After 365 days, they had a persistently increased risk of death (HR = 1.75, CI = 1.62-1.89), IS (HR = 1.40, CI = 1.18-1.67), HF (HR = 2.07, CI = 1.74-2.45), and AMI (HR = 1.28, CI = 1.07-1.53), compared with non-COVID comparators.

conclusionsHospitalized COVID-19 cases continued to have a nearly doubled risk of cardiovascular events and death after the first year of follow-up, whereas nonhospitalized cases had risks comparable to population comparators.

Indexed as

Cardiovascular DiseasesCOVID-19AdultAgedCohort StudiesFemaleHeart FailureHospitalizationHumansMaleMiddle AgedMyocardial InfarctionRegistriesRisk FactorsSARS-CoV-2Swedencardiovascular diseaseCOVID‐19preventionrisk factors

Identifiers

PMID41319157
PMCPMC12789278

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.